Effects of Reverse Transcriptase Inhibitors on Proliferation, Apoptosis, and Migration in Breast Carcinoma Cells

Basit Öğe Kaydı
dc.authoridAtli Sekeroglu, Zulal / 0000-0002-3552-3819
dc.authorwosidAtli Sekeroglu, Zulal / M-3525-2013
dc.contributor.authorSekeroglu, Zulal Atli
dc.contributor.authorSekeroglu, Vedat
dc.contributor.authorKucuk, Nihan
dc.date.accessioned2021-11-01T15:05:39Z
dc.date.available2021-11-01T15:05:39Z
dc.date.issued2021
dc.department[Belirlenecek]
dc.description.abstractHigh telomerase activity in human breast cancer is associated with aggressive tumors resulting in decreased survival. Recent studies have shown that telomerase inhibitors may display anticancer properties in some human cancer cell lines. In the present study, we examined the effects of 4 reverse transcriptase inhibitors (RTIs), used for the treatment of HIV; Abacavir (AC), Lamivudine (LV), Stavudine (SV), and Tenofovir (TF) on proliferation, apoptosis, and migration in the normal human mammary epithelial cell line, hTERT-HME1, and the human breast cancer cell line, MCF-7. Cells were treated with AC, LV, SV, or TF alone or in combination with paclitaxel (PAC), a known drug used to treat breast cancer. Conduct of the thiazolyl blue tetrazolium bromide assay demonstrated that AC, SV, and TF had stronger cytotoxic effects on MCF-7 cells than in hTERT-HME1 cells. The combined treatment of RTIs and PAC caused high rates of cell death in MCF-7 and low rates of cell death in HTERT-HME1 by apoptosis. The percentages of apoptotic cells in the treatment of AC and SV in combination with PAC for 48 and 72 hours were higher than PAC. Significantly increased apoptosis and decreased migration levels were found in MCF-7 cells treated with AC and co-treatment of AC+PAC or SV+PAC than HME1 cells. These treatments can also prevent migration capacity more than PAC. Therefore, a combination strategy based on telomerase inhibitors such as AC or SV and anticancer drugs may be more effective in the treatment of certain breast cancers.
dc.description.sponsorshipScientific Research Funding of Ordu University (Turkey) [AR-1668]en_US
dc.description.sponsorshipThe author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work is supported by the Scientific Research Funding of Ordu University (Turkey) (Project No: AR-1668).en_US
dc.identifier.doi10.1177/1091581820961498
dc.identifier.endpage61en_US
dc.identifier.issn1091-5818
dc.identifier.issn1092-874X
dc.identifier.issue1en_US
dc.identifier.pmid32975457
dc.identifier.scopus2-s2.0-85091455014
dc.identifier.scopusqualityQ3
dc.identifier.startpage52en_US
dc.identifier.urihttps://doi.org/10.1177/1091581820961498
dc.identifier.urihttps://hdl.handle.net/11491/7356
dc.identifier.volume40en_US
dc.identifier.wosWOS:000574750400001
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthor[Belirlenecek]
dc.language.isoen
dc.publisherSage Publications Inc
dc.relation.ispartofInternational Journal Of Toxicology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectreverse transcriptase inhibitorsen_US
dc.subjectproliferationen_US
dc.subjectapoptosisen_US
dc.subjectmigrationen_US
dc.subjectbreast canceren_US
dc.titleEffects of Reverse Transcriptase Inhibitors on Proliferation, Apoptosis, and Migration in Breast Carcinoma Cells
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu